Related references
Note: Only part of the references are listed.The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1
Ken-ichi Fujita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
C. Tanaka et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants
Ophelia Q. P. Yin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
Gender and interindividual variability in pharmacokinetics
Jean-Marie Nicolas et al.
DRUG METABOLISM REVIEWS (2009)
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
A. Davies et al.
LEUKEMIA (2009)
Harmonization of molecular monitoring of CML therapy in Europe
M. C. Mueller et al.
LEUKEMIA (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
J. B. Singer et al.
LEUKEMIA (2007)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
S. Branford et al.
LEUKEMIA (2006)
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Deborah L. White et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study
H Schmidli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Genetics of the variable expression of CYP3A in humans
L Wojnowski
THERAPEUTIC DRUG MONITORING (2004)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
